/PRNewswire/ Immunovia AB (publ) ("Immunovia"), a diagnostic company that develops and sells highly accurate blood tests for the early detection of cancer,.
LUND, Sweden, Oct. 15, 2021 /PRNewswire/ Immunovia AB (publ) ("Immunovia"), a diagnostic company that develops and sells highly accurate blood tests for the early detection of cancer, announced
Annual General Meeting - Immunovia AB
On 6
th May 2021, the Annual General Meeting (AGM) was held in Immunovia AB (publ), 556730-4299. Due to the extraordinary situation following the COVID-19-pandemic, the AGM was carried out through advance voting pursuant to temporary legislation. Below is a summary of the resolutions made at the AGM.
Allocation of the company s available profits
The AGM resolved that the company s available profits, SEK 565,437,678, shall be brought forward and that no dividend shall be made.
Fees for the board and the auditor
The AGM resolved that the chairman of the board shall receive SEK 550,000 and each of the other members of the board shall receive SEK 240,000. Remuneration for committee work will amount to SEK 30,000 for members of the audit and remuneration committees, and SEK 50,000 for the chairmen of the audit and remuneration committees. Travel expenses will be reimbursed in accordance with company policy. Lastly, the auditor s fees are to be p